Mast Therapeutics Inc (NASDAQ:MSTX) was downgraded by investment analysts at Laidlaw to a “neutral” rating in a report released on Wednesday.
Several other analysts have also issued reports on the stock. Maxim Group lowered shares of Mast Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday. Zacks Investment Research upgraded shares of Mast Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, August 30th. Roth Capital restated a “buy” rating and set a $2.00 price target on shares of Mast Therapeutics in a research report on Monday, August 1st. Finally, Canaccord Genuity restated a “buy” rating and set a $3.00 price target on shares of Mast Therapeutics in a research report on Thursday, July 28th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $3.33.
Shares of Mast Therapeutics (NASDAQ:MSTX) opened at 0.1331 on Wednesday. The company’s market capitalization is $28.19 million. Mast Therapeutics has a 12 month low of $0.10 and a 12 month high of $0.71. The company has a 50-day moving average price of $0.45 and a 200-day moving average price of $0.38.
Mast Therapeutics (NASDAQ:MSTX) last posted its quarterly earnings results on Tuesday, August 9th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.01. On average, equities analysts anticipate that Mast Therapeutics will post ($0.21) EPS for the current year.
An institutional investor recently raised its position in Mast Therapeutics stock. Vanguard Group Inc. boosted its position in Mast Therapeutics Inc (NASDAQ:MSTX) by 18.2% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 5,996,047 shares of the company’s stock after buying an additional 923,507 shares during the period. Vanguard Group Inc. owned approximately 3.11% of Mast Therapeutics worth $2,818,000 as of its most recent SEC filing.
Receive News & Ratings for Mast Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mast Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.